Skip to main content
Premium Trial:

Request an Annual Quote

FDA Authorizes Nanobiosym Zika Test

NEW YORK (GenomeWeb) – The US Food and Drug Administration has granted Emergency Use Authorization (EUA) to Nanobiosym's Gene-Radar Zika virus test, the company said today.

According to Nanobiosym, the test is based on its Gene-Radar portable diagnostic platform and can qualitatively detect Zika RNA in human serum from individuals meeting the Centers for Disease Control and Prevention's Zika virus clinical and/or epidemiological criteria.

"This FDA EUA represents a major milestone towards realizing our deeper vision: to decentralize, personalize, and mobilize the next generation of healthcare," Nanobiosym Chairman and CEO Anita Goel said in a statement.